NCT05115903View on ClinicalTrials.gov

Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

July 1, 2024

Study Completion Date

August 1, 2024

Conditions
Axial Spondyloarthritis
Interventions
DRUG

Tapered doses of TNFi

To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing dose intervals as specified

DRUG

Standard dose of TNFi

To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)

Trial Locations (1)

M5T 2S8

University Health Network - Toronto Western Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER